{"id":2942,"date":"2015-02-08T11:37:48","date_gmt":"2015-02-08T11:37:48","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2942"},"modified":"2015-02-03T11:38:32","modified_gmt":"2015-02-03T11:38:32","slug":"angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/","title":{"rendered":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren"},"content":{"rendered":"<p>AMB 2012, 46, 95b Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren Das Angioneurotische \u00d6dem oder Angio\u00f6dem ist eine seltene, aber potenziell gef\u00e4hrliche unerw\u00fcnschte Arzneimittelwirkung (UAW) bei Einnahme von Angiotensin-Konversions-Enzym (ACE)-Hemmern (ACE-H; vgl.\u00a01). Das ACE wandelt das Blutdruck-inaktive Angiotensin\u00a0I (A\u00a0I) in das aktive A\u00a0II um. Au\u00dferdem wirkt es als Kininase, die den Abbau von Bradykinin f\u00f6rdert. Es [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2012, 46, 95b Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren Das Angioneurotische \u00d6dem oder Angio\u00f6dem ist eine seltene, aber potenziell gef\u00e4hrliche unerw\u00fcnschte Arzneimittelwirkung (UAW) bei Einnahme von Angiotensin-Konversions-Enzym (ACE)-Hemmern (ACE-H; vgl.\u00a01). Das ACE wandelt das Blutdruck-inaktive Angiotensin\u00a0I (A\u00a0I) in das aktive A\u00a0II um. Au\u00dferdem wirkt es als Kininase, die den Abbau von Bradykinin f\u00f6rdert. Es [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[954,1015,727,728,1279,1280,1281,338,339,1282,1283,340,341,1284,343,81,80,82,345],"class_list":["post-2942","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-aliskiren","tag-angioneurotisches-oedem","tag-angiooedem","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-sartane"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren<\/title>\n<meta name=\"description\" content=\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren\" \/>\n<meta property=\"og:description\" content=\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-08T11:37:48+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren\",\"datePublished\":\"2015-02-08T11:37:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/\"},\"wordCount\":834,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"ACE-Hemmer\",\"Aliskiren\",\"Angioneurotisches \u00d6dem\",\"Angio\u00f6dem\",\"Angiotensin-II-Antagonisten\",\"Angiotensin-II-Blocker\",\"Angiotensin-II-Inhibitoren\",\"Angiotensin-II-Rezeptor-Antagonisten\",\"Angiotensin-II-Rezeptor-Blocker\",\"Angiotensin-II-Rezeptor-Inhibitoren\",\"AT-II-Antagonisten\",\"AT-II-Blocker\",\"AT-II-Inhibitoren\",\"AT-II-Rezeptor-Antagonisten AT-II-Rezeptor-Blocker\",\"AT-II-Rezeptor-Inhibitoren\",\"Beta-Blocker\",\"Betablocker\",\"Betarezeptoren-Blocker\",\"Sartane\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/\",\"name\":\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2015-02-08T11:37:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren","description":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/","og_locale":"de_DE","og_type":"article","og_title":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren","og_description":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2015-02-08T11:37:48+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren","datePublished":"2015-02-08T11:37:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/"},"wordCount":834,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["ACE-Hemmer","Aliskiren","Angioneurotisches \u00d6dem","Angio\u00f6dem","Angiotensin-II-Antagonisten","Angiotensin-II-Blocker","Angiotensin-II-Inhibitoren","Angiotensin-II-Rezeptor-Antagonisten","Angiotensin-II-Rezeptor-Blocker","Angiotensin-II-Rezeptor-Inhibitoren","AT-II-Antagonisten","AT-II-Blocker","AT-II-Inhibitoren","AT-II-Rezeptor-Antagonisten AT-II-Rezeptor-Blocker","AT-II-Rezeptor-Inhibitoren","Beta-Blocker","Betablocker","Betarezeptoren-Blocker","Sartane"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/","name":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2015-02-08T11:37:48+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2942"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2942\/revisions"}],"predecessor-version":[{"id":2943,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2942\/revisions\/2943"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}